Since early December 2019, the COVID-19 pandemic has impacted global society: over 400 million people have been infected with SARS-CoV-2, and there have been nearly 6 million deaths worldwide (1 [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025328 | PMC |
| http://dx.doi.org/10.3390/genes13040676 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A simple and effective method to remove pigments from heterologous secretory proteins expressed in Pichia pastoris.
Adv Biotechnol (Singap)
February 2024
CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China.
Pichia pastoris is a popular yeast host for high-level heterologous expression of proteins on an industrial scale owing to its reliable expression, robust growth, high fermentation density, and easy genetic manipulation and cultivation at a relatively low cost. Of particular interest is its high secretion efficiency for small proteins including insulin, human serum albumin, vaccines, enzymes, and llama-derived heavy-chain only antibodies (nanobodies) for pharmaceutical and research applications. However, a recurring challenge in using P.
View Article and Find Full Text PDFA human antibody derived from original SARS-CoV-2 infection effectively neutralizes omicron.
Adv Biotechnol (Singap)
January 2024
Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China.
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) Variants of Concern (VOCs), such as the Omicron sub-variants, present significant challenges in pandemic control due to their capacity to escape antibodies and breach vaccine protections. Discovering antibodies that can tolerate mutations in VOCs and understanding their underlying mechanisms is crucial for developing therapeutics for COVID-19 patients, particularly those for whom other therapies may be unsuitable. Here, we report the neutralization of the Omicron variant by FD20, a broadly active human monoclonal antibody.
View Article and Find Full Text PDFLinking the function of -acting RNA elements to coronavirus replication using interactomes.
J Gen Virol
January 2025
Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, Taichung 40227, Taiwan, ROC.
RNA structures that are functionally important are defined as -acting RNA elements because their functions cannot be compensated for in trans. The -acting RNA elements in the 3' UTR of coronaviruses are important for replication; however, the mechanism linking the -acting RNA elements to their replication function remains to be established. In the present study, a comparison of the biological processes of the interactome and the replication efficiency between the 3' UTR -acting RNA elements in coronaviruses, including severe acute respiratory syndrome coronavirus 2, suggests that (i) the biological processes, including translation, protein folding and protein stabilization, derived from the analysis of the -acting RNA element interactome and (ii) the architecture of the -acting RNA elements and their interactomes are highly correlated with coronavirus replication.
View Article and Find Full Text PDFDysregulation of lung epithelial cell homeostasis and immunity contributes to Middle East respiratory syndrome coronavirus disease severity.
mSphere
January 2025
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Coronaviruses (CoV) emerge suddenly from animal reservoirs to cause novel diseases in new hosts. Discovered in 2012, the Middle East respiratory syndrome coronavirus (MERS-CoV) is endemic in camels in the Middle East and is continually causing local outbreaks and epidemics. While all three newly emerging human CoVs from the past 20 years (SARS-CoV, SARS-CoV-2, and MERS-CoV) cause respiratory disease, each CoV has unique host interactions that drive differential pathogeneses.
View Article and Find Full Text PDFA Framework for Assessing Viral Pathogens: A Key Element of the BARDA Emerging Infectious Diseases Strategy.
Health Secur
January 2025
Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Division of Research, Innovation, and Ventures; and Robert A. Johnson, PhD, is Director, Medical Countermeasures Program; all at the Biomedical Advanced Research and Development Authority, Washington, DC. Gerald R. Kovacs, PhD, is a Senior Advisor; Huyen Cao, MD, is a Senior Clinical Studies Analyst; Christopher Dale, PhD, and Mark Michalik, MBA, are Senior Subject Matter Experts; Mario H. Skiadopoulos, PhD, is a Preclinical Drug Development Subject Matter Expert; and Xiaomi Tong, PhD, is a Senior Regulatory Affairs Subject Matter Expert; all at Tunnell Government Services, Berwyn, PA. Suchismita Chandran, PhD, is a Lead Associate, and Michael Rowe, MS, is a Senior Consultant; both at Booz Allen Hamilton, McLean, VA. Ethan J. Fritch, PhD, is an ORISE Fellow, Oak Ridge Institute for Science and Education, Oak Ridge, TN. George Robertson, PhD, is Chief Scientific Officer, Cambra Consulting, Inc., Woodbridge, VA.
The COVID-19 pandemic has revealed the need for nations to prepare more effectively for emerging infectious diseases. Preparing for these threats requires a multifaceted approach that includes assessing pathogen threat, building flexible capabilities for rapid medical countermeasure (MCM) development, and exercising, maintaining, and improving those response capabilities. The Biomedical Advanced Research and Development Authority (BARDA) promotes the advanced development of MCMs in response to natural and manmade threats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!